GlassScriptPhysician profile
Luis A Gonzales
NPI 1578641825
$8,876.55
in general payments reported to CMS, 2019-2025
21 companies · $765 in 2025
The $765 reported for 2025 was more than what 82% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,866 · 2020: $950 · 2021: $986 · 2022: $603 · 2023: $668 · 2024: $1,039 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,470.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,140.74 | 2019-2023 | Invega Trinza, Invega Sustenna |
| Axsome Therapeutics, INC. | $1,072.45 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $978.20 | 2019-2024 | Rexulti |
| Alkermes, INC. | $784.40 | 2019-2022 | |
| Allergan, INC. | $740.28 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $566.61 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $565.11 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $513.92 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $440.73 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $398.37 | 2019-2021 | |
| Lundbeck LLC | $369.91 | 2019-2022 | |
| Indivior INC. | $327.12 | 2019 | |
| Vanda Pharmaceuticals INC. | $250.00 | 2024-2025 | Fanapt |
| Neuronetics, INC. | $214.29 | 2024 | Neurostar Tms Therapy System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $170.14 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $124.99 | 2019 | |
| Abbvie INC. | $74.31 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $55.04 | 2021-2022 | |
| Noven Therapeutics, LLC | $48.22 | 2020-2021 | |
| Abbott Laboratories | $23.16 | 2023 | Proclaim |
| Novo Nordisk INC | $18.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Gonzales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.